CLOs on the Move

PuraCap

www.puracap.com

 
EpiCeram® Controlled Release Skin Barrier Emulsion is a leading prescription product that has the ability to help repair and heal the skin barrier through a unique mode-of-action different from other medications and eczema treatments. Only EpiCeram® co...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Physician's Choice

Physician's Choice, Inc. is a Destin, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

RESTAT

RESTAT is a West Bend, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanCare

PanCare Health Offers Health Care Services In Multiple Locations, Including Freeport And Bonifay, FL For Urgent Care, Affordable Therapy, And More. Call Today!

Aralez

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients` lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez`s Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).